Second-generation  ||| S:0 E:18 ||| JJ
antipsychotic  ||| S:18 E:32 ||| JJ
long-acting  ||| S:32 E:44 ||| JJ
injections ||| S:44 E:54 ||| NNS
:  ||| S:54 E:56 ||| :
systematic  ||| S:56 E:67 ||| JJ
review  ||| S:67 E:74 ||| NN
Second-generation  ||| S:74 E:92 ||| JJ
antipsychotics  ||| S:92 E:107 ||| NNS
( ||| S:107 E:108 ||| -LRB-
SGAs ||| S:108 E:112 ||| NNP
)  ||| S:112 E:114 ||| -RRB-
represent  ||| S:114 E:124 ||| VBP
an  ||| S:124 E:127 ||| DT
advance  ||| S:127 E:135 ||| NN
in  ||| S:135 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
long-term  ||| S:142 E:152 ||| JJ
management  ||| S:152 E:163 ||| NN
of  ||| S:163 E:166 ||| IN
schizophrenia ||| S:166 E:179 ||| NN
.  ||| S:179 E:181 ||| .
To  ||| S:181 E:184 ||| TO
review  ||| S:184 E:191 ||| VB
the  ||| S:191 E:195 ||| DT
available  ||| S:195 E:205 ||| JJ
evidence  ||| S:205 E:214 ||| NN
concerning  ||| S:214 E:225 ||| VBG
SGA  ||| S:225 E:229 ||| NNP
long-acting  ||| S:229 E:241 ||| JJ
injections  ||| S:241 E:252 ||| NNS
( ||| S:252 E:253 ||| -LRB-
LAIs ||| S:253 E:257 ||| NNP
) ||| S:257 E:258 ||| -RRB-
.  ||| S:258 E:260 ||| .
A  ||| S:260 E:262 ||| DT
systematic  ||| S:262 E:273 ||| JJ
review  ||| S:273 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
the  ||| S:283 E:287 ||| DT
literature  ||| S:287 E:298 ||| NN
was  ||| S:298 E:302 ||| VBD
conducted  ||| S:302 E:312 ||| VBN
using  ||| S:312 E:318 ||| VBG
PubMed ||| S:318 E:324 ||| JJ
.  ||| S:324 E:326 ||| .
Risperidone  ||| S:326 E:338 ||| JJ
long-acting  ||| S:338 E:350 ||| JJ
injection  ||| S:350 E:360 ||| NN
was  ||| S:360 E:364 ||| VBD
the  ||| S:364 E:368 ||| DT
first  ||| S:368 E:374 ||| JJ
licensed  ||| S:374 E:383 ||| JJ
SGA-LAI  ||| S:383 E:391 ||| JJ
compound  ||| S:391 E:400 ||| NN
and  ||| S:400 E:404 ||| CC
is  ||| S:404 E:407 ||| VBZ
effective  ||| S:407 E:417 ||| JJ
in  ||| S:417 E:420 ||| IN
the  ||| S:420 E:424 ||| DT
long-term  ||| S:424 E:434 ||| JJ
management  ||| S:434 E:445 ||| NN
of  ||| S:445 E:448 ||| IN
schizophrenia ||| S:448 E:461 ||| NN
,  ||| S:461 E:463 ||| ,
with  ||| S:463 E:468 ||| IN
a  ||| S:468 E:470 ||| DT
safety  ||| S:470 E:477 ||| NN
profile  ||| S:477 E:485 ||| NN
similar  ||| S:485 E:493 ||| JJ
to  ||| S:493 E:496 ||| TO
that  ||| S:496 E:501 ||| DT
of  ||| S:501 E:504 ||| IN
oral  ||| S:504 E:509 ||| JJ
risperidone ||| S:509 E:520 ||| NN
.  ||| S:520 E:522 ||| .
Olanzapine  ||| S:522 E:533 ||| JJ
pamoate  ||| S:533 E:541 ||| NN
has  ||| S:541 E:545 ||| VBZ
recently  ||| S:545 E:554 ||| RB
been  ||| S:554 E:559 ||| VBN
approved  ||| S:559 E:568 ||| VBN
in  ||| S:568 E:571 ||| IN
Europe ||| S:571 E:577 ||| NNP
.  ||| S:577 E:579 ||| .
In  ||| S:579 E:582 ||| IN
terms  ||| S:582 E:588 ||| NNS
of  ||| S:588 E:591 ||| IN
efficacy ||| S:591 E:599 ||| NN
,  ||| S:599 E:601 ||| ,
at  ||| S:601 E:604 ||| IN
injection  ||| S:604 E:614 ||| NN
intervals  ||| S:614 E:624 ||| NNS
of  ||| S:624 E:627 ||| IN
up  ||| S:627 E:630 ||| RB
to  ||| S:630 E:633 ||| TO
4  ||| S:633 E:635 ||| CD
weeks  ||| S:635 E:641 ||| NNS
it  ||| S:641 E:644 ||| PRP
appears  ||| S:644 E:652 ||| VBZ
comparable  ||| S:652 E:663 ||| JJ
to  ||| S:663 E:666 ||| TO
oral  ||| S:666 E:671 ||| JJ
olanzapine ||| S:671 E:681 ||| NN
,  ||| S:681 E:683 ||| ,
although  ||| S:683 E:692 ||| IN
the  ||| S:692 E:696 ||| DT
potential  ||| S:696 E:706 ||| NN
for  ||| S:706 E:710 ||| IN
; ||| S:710 E:711 ||| :
post-injection  ||| S:711 E:726 ||| JJ
syndrome ||| S:726 E:734 ||| NN
'  ||| S:734 E:736 ||| ''
( ||| S:736 E:737 ||| -LRB-
delirium ||| S:737 E:745 ||| LS
)  ||| S:745 E:747 ||| -RRB-
calls  ||| S:747 E:753 ||| VBZ
for  ||| S:753 E:757 ||| IN
additional  ||| S:757 E:768 ||| JJ
safety  ||| S:768 E:775 ||| NN
considerations ||| S:775 E:789 ||| NNS
.  ||| S:789 E:791 ||| .
Paliperidone  ||| S:791 E:804 ||| JJ
palmitate  ||| S:804 E:814 ||| NN
is  ||| S:814 E:817 ||| VBZ
currently  ||| S:817 E:827 ||| RB
under  ||| S:827 E:833 ||| IN
review  ||| S:833 E:840 ||| NN
with  ||| S:840 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
licensing  ||| S:849 E:859 ||| NN
authorities ||| S:859 E:870 ||| NNS
.  ||| S:870 E:872 ||| .
It  ||| S:872 E:875 ||| PRP
also  ||| S:875 E:880 ||| RB
affords  ||| S:880 E:888 ||| VB
the  ||| S:888 E:892 ||| DT
potential  ||| S:892 E:902 ||| JJ
advantage  ||| S:902 E:912 ||| NN
of  ||| S:912 E:915 ||| IN
monthly  ||| S:915 E:923 ||| JJ
dosing ||| S:923 E:929 ||| NN
.  ||| S:929 E:931 ||| .
More  ||| S:931 E:936 ||| RBR
long-term  ||| S:936 E:946 ||| JJ
comparisons  ||| S:946 E:958 ||| NNS
of  ||| S:958 E:961 ||| IN
SGA-LAIs  ||| S:961 E:970 ||| JJ
with  ||| S:970 E:975 ||| IN
oral  ||| S:975 E:980 ||| JJ
SGAs  ||| S:980 E:985 ||| NN
as  ||| S:985 E:988 ||| IN
well  ||| S:988 E:993 ||| RB
as  ||| S:993 E:996 ||| RB
with  ||| S:996 E:1001 ||| IN
first-generation  ||| S:1001 E:1018 ||| JJ
antipsychotic  ||| S:1018 E:1032 ||| JJ
LAIs  ||| S:1032 E:1037 ||| NNS
are  ||| S:1037 E:1041 ||| VBP
needed ||| S:1041 E:1047 ||| VBN
.  ||| S:1047 E:1049 ||| .
These  ||| S:1049 E:1055 ||| DT
studies  ||| S:1055 E:1063 ||| NNS
should  ||| S:1063 E:1070 ||| MD
include  ||| S:1070 E:1078 ||| VB
cost-effectiveness  ||| S:1078 E:1097 ||| JJ
data ||| S:1097 E:1101 ||| NNS
.  ||| S:1101 E:1103 ||| .
